High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
This study is looking at whether a higher dose flu vaccine works better than a standard dose flu vaccine for people who have received a lung transplant. We know that lung transplant recipients are more likely to get very sick from the flu. This study will compare two doses of Fluzone High-Dose Quadrivalent Inactivated Influenza Vaccine to two doses of Fluzone Quadrivalent. Researchers want to see if the high-dose vaccine creates a stronger immune response (more antibodies) and if it is just as safe as the standard dose vaccine. You may be able to join if you are a lung transplant recipient, aged 16 or older, and had your transplant between 1 month and 3 years ago. The study aims to enroll 270 participants, but the current recruitment status is unclear.
- Study design
- This is a Phase 2, multi-center, double-blind, randomized controlled study comparing two different flu vaccines. It plans to enroll 270 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your antibody levels will be measured 56 days after vaccination, and reactions will be monitored for 7 days post-vaccination.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Natasha Halasa, MD. MPH · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Geometric Mean Titers of influenza vaccine antibodies.Day 56 (post-vaccination)
Antibody titers will be measured by hemagglutination inhibition assay.
- The number of participants reporting solicited injection site reactions and systemic reactions.Within 7 days post-vaccination
Post-vaccination local adverse events (pain, tenderness, swelling/induration, erythema/redness, swelling/induration size, and erythema/redness size) and systemic adverse events (Fatigue/malaise, headache, nausea, body ache/myalgia (not at the injection site), general activity level, vomiting, and fever).